Sarepta COO exercises options for 7,450 shares

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan exercised stock options and acquired additional common shares.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan exercised stock options and acquired additional common shares. On February 26, 2026, he exercised options for 2,069 shares and 5,381 shares of common stock at an exercise price of $13.71 per share. These transactions increased his directly held common stock to 200,750 shares, according to the filing footnote, and involved no reported open-market sales.

Insider Trade Summary

7,450 shares exercised/converted

Exercise 4 txns

Insider Estepan Ian Michael

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	2,069	$0.00	$0.00
Exercise	Stock Option (right to buy)	5,381	$0.00	$0.00
Exercise	Common Stock	2,069	$13.71	$28K
Exercise	Common Stock	5,381	$13.71	$74K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 200,750 shares (Direct)

Footnotes (1)

1. F1. Represents shares held by the Reporting Person after the exercise of a stock option.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) report for Ian Michael Estepan?

Ian Michael Estepan exercised stock options to acquire additional Sarepta Therapeutics common shares. He converted option awards into 2,069 and 5,381 shares of common stock, increasing his direct ownership as disclosed in the Form 4 filing and related footnote.

How many Sarepta Therapeutics (SRPT) shares did the COO acquire in this Form 4?

The COO acquired a total of 7,450 Sarepta Therapeutics common shares through option exercises. The Form 4 shows separate exercises for 2,069 and 5,381 shares, both recorded as derivative exercises rather than open-market purchases, increasing his reported direct holdings.

What was the exercise price of the Sarepta Therapeutics (SRPT) stock options?

The reported exercise price of the Sarepta Therapeutics stock options was $13.71 per share. This price applied to both the 2,069-share and 5,381-share option exercises, converting previously granted options into directly held common stock, as detailed in the Form 4 transaction table.

Did the Sarepta Therapeutics (SRPT) COO sell any shares in this Form 4 filing?

The Form 4 does not report any sales; all transactions are option exercises classified as acquisitions. Each entry carries code “M” for derivative exercise or conversion, and the summary shows zero sell transactions, indicating no disposal of shares in this filing.

What is Ian Michael Estepan’s direct Sarepta Therapeutics (SRPT) shareholding after the transactions?

After the option exercises, Ian Michael Estepan directly holds 200,750 Sarepta Therapeutics common shares. The filing’s footnote explains that this figure represents shares held following the option exercise, reflecting his updated direct ownership position as of the reported transaction date.

How are the Sarepta Therapeutics (SRPT) Form 4 transactions classified?

All reported transactions are classified as derivative exercises or conversions with code “M.” They involve stock options converting into common stock and are labeled as acquisitions, not open-market buys or sales, according to the transaction descriptions and the Form 4 transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Estepan Ian Michael

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		M(1)		2,069	A	$13.71	195,369	D
Common Stock	02/26/2026		M(1)		5,381	A	$13.71	200,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.71	02/26/2026		M			2,069	02/28/2017	02/28/2026	Common Stock	2,069	$0	0	D
Stock Option (right to buy)	$13.71	02/26/2026		M			5,381	02/28/2017	02/28/2026	Common Stock	5,381	$0	0	D

Explanation of Responses:

1. Represents shares held by the Reporting Person after the exercise of a stock option.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.